HIC1 and cancer: The other two-gene cassette comprising of SOX1+HIC1 exhibited combined sensitivity of 80.0% with a specificity of 96% in serum CFDNA [AUC = 0.93] in differentiating malignant EOC samples and cancer-free healthy control serum samples.